Digestive Disease Treatment in Nassau County NY focuses not only on disorders of the stomach and intestinal tract but on the liver disease as well. When people have been diagnosed with hepatitis C, a digestive disease clinic helps them manage this chronic health disorder. Contact GastroCare LI for information about effective pharmaceutical therapy for hepatitis C.
It is difficult to estimate how many U.S. residents are infected with the hepatitis C virus since health officials assume large numbers of them have not been diagnosed. The U.S. Centers for Disease Control notes statistics indicating that some 3.5 million residents probably are infected, but the number might be as high as 4.7 million. In up to 25 percent of patients, the virus disappears without any treatment. In other people, the condition becomes chronic. They develop distinct symptoms that lead them to see a doctor. Some symptoms that lead people to see a doctor and become diagnosed include unexplained joint pain, chronic nausea, frequent abdominal pain, fatigue, or oddly colored urine or stools.
People become infected with hepatitis C in various ways. It involves some transfer of bodily fluids from an infected person to another individual. Sharing syringes for drug use, and having sexual intercourse are examples. Sharing objects that could transfer blood, such as shaving razors, is another possibility. A health care worker might be accidentally poked with a contaminated needle in a hospital or clinic. Before blood donations were screened, patients could acquire hepatitis C by receiving blood. This is extremely unlikely now, however.
After diagnosis, patients can begin digestive disease treatment in Nassau County NY to reduce symptoms, regain quality of life and improve their chances of staying alive for many years to come. Patients receive different types of medications that have proved to be effective for treating hepatitis C. Treatment may result in a strong enough response that the virus is no longer found in the blood. Improvements in pharmaceutical products for the disease mean that a large percentage of patients are effectively cured within three to six months. Up to 95 percent of patients have achieved this result during clinical trials.
